NEW YORK (GenomeWeb) – With a growing portfolio of tests either CE marked for sale in Europe or going through the US Food and Drug Administration process, Cepheid Chairman and CEO John Bishop said the firm sees a "significant opportunity" ahead in both the US and international markets.
The firm also has plans to expand its sales force and is targeting growth in the CLIA test market.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try GenomeWeb Premium now.
You may already have institutional access!
Check if I qualify.
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.